Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
Journal of Clinical Medicine · 10.02.2023 · 12 (4) · 1438
DOI: 10.3390/jcm12041438 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 10.02.2023. Verfasst von Yi-Ze Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi.
Abstract (Originalsprache)
More and more clinical trials have explored the role of liquid biopsy in the diagnosis and treatment of EGFR-mutated NSCLC. In certain circumstances, liquid biopsy has unique advantages and offers a new way to detect therapeutic targets, analyze drug resistance mechanisms in advanced patients, and monitor MRD in patients with operable NSCLC. Although its potential cannot be ignored, more evidence is needed to support the transition from the research stage to clinical application. We reviewed the latest progress in research on the efficacy and resistance mechanisms of targeted therapy for advanced NSCLC patients with plasma ctDNA EGFR mutation and the evaluation of MRD based on ctDNA detection in perioperative and follow-up monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
ORCID-Profile: Yi-Ze Li, Hong-Mei Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi
Zitieren
APA
Li, Y. Z., Kong, S. N., Liu, Y. P., Yang, Y., & Zhang, H. M. (2023). Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?. Journal of Clinical Medicine, 12(4), 1438. https://doi.org/10.3390/jcm12041438
Vancouver
Li YZ, Kong SN, Liu YP, Yang Y, Zhang HM. Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?. Journal of Clinical Medicine. 2023;12(4):1438. doi:10.3390/jcm12041438
BibTeX
@article{Li2023,
author = {Li, Yi-Ze and Kong, Sheng-Nan and Liu, Yun-Peng and Yang, Yue and Zhang, Hong-Mei},
title = {Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {1438},
doi = {10.3390/jcm12041438}
}
EUVIMED